International Journal of Infectious Diseases最新文献

{"title":"Oropouche virus infection: Differential clinical outcomes and emerging global concerns of vertical transmission and fatal cases","authors":"Giancarlo Ceccarelli , Francesco Branda , Fabio Scarpa , Massimo Ciccozzi , Luiz Carlos Junior Alcantara , Marta Giovanetti","doi":"10.1016/j.ijid.2024.107295","DOIUrl":"10.1016/j.ijid.2024.107295","url":null,"abstract":"","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"150 ","pages":"Article 107295"},"PeriodicalIF":4.8,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute cholangitis caused by coinfection with zoonotic pathogens of Gallibacterium anatis and Enterococcus cecorum: A case report","authors":"Masahiro Kodana ,&nbsp;Kazuo Imai ,&nbsp;Tetsuyoshi Takayama ,&nbsp;Masaomi Suzuki ,&nbsp;Toru Kawamura ,&nbsp;Ryuha Omachi ,&nbsp;Hiroshi Asano ,&nbsp;Takuya Maeda","doi":"10.1016/j.ijid.2024.107292","DOIUrl":"10.1016/j.ijid.2024.107292","url":null,"abstract":"<div><h3>Background</h3><div><em>Gallibacterium anatis</em> and <em>Enterococcus cecorum</em> are considered to be emerging infectious pathogens in poultry, particularly in the European Union. These bacteria are isolated on rare occasions from immunocompromised hosts and cause opportunistic infections associated with the ingestion of contaminated food. Here, we report the first case of <em>G. anatis</em> and <em>E. cecorum</em> coinfection in an immunocompetent host and clarify the genomic characteristics of these bacteria.</div></div><div><h3>Case presentation</h3><div>A 78-year-old Japanese man diagnosed with acute cholangitis as a result of a common bile duct stone was hospitalized in 2021. He was treated with endoscopic papillary large-balloon dilation and antibiotics. His blood culture was positive for <em>G. anatis</em> and <em>E. cecorum</em>. Whole-genome sequencing identified that our isolate of <em>G. anatis</em> belongs to a highly virulent biovar <em>haemolytica</em> strain and our isolate of <em>E. cecorum</em> had multidrug resistance genes, which have commonly been found in U.S. strains.</div></div><div><h3>Conclusion</h3><div>A common bile duct stone that impairs bile flow is a risk factor for <em>G. anatis</em> and <em>E. cecorum</em> infection in an immunocompetent host. This report indicates the need for further surveillance of <em>G. anatis</em> and <em>E. cecorum</em> in animals as well as for investigation of their pathogenesis in humans.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"150 ","pages":"Article 107292"},"PeriodicalIF":4.8,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kinetics of hepatitis B virus replication in anti-HBc positive/HBsAg-negative people with HIV switching to tenofovir sparing therapy","authors":"Romina Salpini ,&nbsp;Stefano D'Anna ,&nbsp;Mohammad Alkhatib ,&nbsp;Lorenzo Piermatteo ,&nbsp;Alessandro Tavelli ,&nbsp;Livia Benedetti ,&nbsp;Eugenia Quiros Roldan ,&nbsp;Antonella Cingolani ,&nbsp;Chiara Papalini ,&nbsp;Stefania Carrara ,&nbsp;Vincenzo Malagnino ,&nbsp;Massimo Puoti ,&nbsp;Loredana Sarmati ,&nbsp;Francesca Ceccherini-Silberstein ,&nbsp;Carlo Federico Perno ,&nbsp;Antonella d'Arminio Monforte ,&nbsp;Valentina Svicher","doi":"10.1016/j.ijid.2024.107294","DOIUrl":"10.1016/j.ijid.2024.107294","url":null,"abstract":"<div><h3>Objectives</h3><div>To unravel the still unexplored HBV-replicative kinetics in anti-HBc-positive/HBsAg-negative people-with-HIV (PWH) suspending tenofovir disoproxil-fumarate/tenofovir-alafenamide (TDF/TAF).</div></div><div><h3>Methods</h3><div>A total of 101 anti-HBc-positive/HBsAg-negative PWH switching to TDF/TAF-sparing therapy were included. Serum HBV-DNA and HBV-RNA were quantified by droplet-digital-PCR at switching (T0), within 12 months (T1) and 12-24 months postswitch (T2).</div></div><div><h3>Results</h3><div>At T0, 33.7% had cryptic HBV-DNA (undetected by commercial assays, median [interquartile range (IQR)]: 2 [1-5] IU/mL) and 22% were positive to HBV-RNA alone (median [IQR]: 4 [3-4] IU/mL), indicating an active HBV-reservoir despite HBsAg-negativity and TDF/TAF-pressure. Notably, anti-HBs-titer &lt;100 mIU/mL independently correlated with cryptic HBV-DNA at T0 (OR [95% CI]: 2.6 [1.02-6.5], <em>P</em> = 0.04). After TDF/TAF-withdrawal, the rate of PWH achieving HBV-DNA &gt;10 IU/mL increased from 12.9% at T1 to 42.6% at T2 (<em>P</em> &lt; 0.0001). Likewise, a rise from 2 to 11% was observed for HBV-DNA &gt;100 IU/mL (<em>P</em> = 0.02); median (IQR) HBV-DNA: 579 (425-770) IU/mL. Notably, HBV-DNA &gt;10 IU/mL at T2 occurred in 70% of PWH with cryptic HBV-DNA, in 38.5% with HBV-RNA alone and in 25% negative to both HBV-markers at T0 (<em>P</em> = 0.01). Cryptic HBV-DNA at T0 and lower nadir CD4+ T-cell-count independently predicted HBV-DNA &gt;10 IU/mL at T2 (OR [95% CI]: 8.2 [1.7-40.6], <em>P</em> = 0.01; OR [95% CI]: 8.1 [1.3-52.1], <em>P</em> = 0.03). Lastly, persistent HBV-DNA positivity was independently associated with a reduced CD4+ T-cell recovery at T2 (OR [95% CI]: 0.07 [0.01-0.77], <em>P</em> = 0.03).</div></div><div><h3>Conclusion</h3><div>This study underlines the importance to regularly monitor anti-HBc-positive/HBsAg-negative PWH undergoing TDF/TAF-sparing regimen and the role of highly-sensitive HBV markers in optimizing their management.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"150 ","pages":"Article 107294"},"PeriodicalIF":4.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total burden of hepatitis B and C attributed to injecting drug use in 204 countries and territories from 1990 to 2021: Analyses based on the Global Burden of Disease Study 2021","authors":"Liang Huang ,&nbsp;Xiaoyu Chen ,&nbsp;Zhaojun Wang","doi":"10.1016/j.ijid.2024.107293","DOIUrl":"10.1016/j.ijid.2024.107293","url":null,"abstract":"<div><h3>Objectives</h3><div>This study assesses the global, regional, and national burden of hepatitis B virus (HBV) and hepatitis C virus (HCV) related to injecting drug use (IDU) from 1990 to 2021.</div></div><div><h3>Methods</h3><div>Data from the Global Burden of Disease Study 2021 were analyzed to quantify deaths, age-standardized mortality rates (ASMR), disability-adjusted life years (DALYs), and age-standardized DALYs rates (ASDR) due to HBV and HCV from IDU across 204 countries. Trends were evaluated using estimated annual percentage change. Analyzing the association between ASDR and SDI using a loess regression model.</div></div><div><h3>Results</h3><div>From 1990 to 2021, the global burden of deaths and DALYs due to HBV and HCV attributed to IDU showed an increasing trend, especially among males, whose mortality rates were significantly higher than females. In 2021, global deaths due to HBV from IDU were 13,050.8, with an ASMR of 0.15 per 100,000 and an ASDR of 5.3, both showing an increasing trend with estimated annual percentage changes (EAPCs) of 1.09 and 0.96, respectively. HCV deaths reached 231,764.4, with an ASMR of 2.68 (EAPC: 0.38) and a relatively stable ASDR trend (EAPC: 0.01). Although raw death rates for HCV have increased, the ASMR and ASDR have remained stable or slightly declined, highlighting different trends across sexes and regions. India had the highest national deaths, while the highest ASDRs were in the Republic of Moldova (HBV) and Mongolia (HCV). South Asia recorded the highest regional deaths for both HBV and HCV. Positive correlations between ASDRs for HBV and HCV with SDI were observed.</div></div><div><h3>Conclusion</h3><div>The burden of HBV and HCV due to IDU has increased from 1990 to 2021, especially among males, with significant regional and national disparities. Targeted drug prohibition interventions and policies are needed.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"150 ","pages":"Article 107293"},"PeriodicalIF":4.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-pharmaceutical interventions to reduce influenza transmission in households: a systematic review and meta-analysis","authors":"Jessica Y. Wong ,&nbsp;Wey Wen Lim ,&nbsp;Justin K. Cheung ,&nbsp;Caitriona Murphy ,&nbsp;Eunice Y.C. Shiu ,&nbsp;Jingyi Xiao ,&nbsp;Dongxuan Chen ,&nbsp;Yanmin Xie ,&nbsp;Mingwei Li ,&nbsp;Hualei Xin ,&nbsp;Michelle Szeto ,&nbsp;Sammi Choi ,&nbsp;Benjamin J. Cowling","doi":"10.1016/j.ijid.2024.107291","DOIUrl":"10.1016/j.ijid.2024.107291","url":null,"abstract":"<div><h3>Background</h3><div>Influenza pandemic plans often recommend non-pharmaceutical interventions (NPIs) in household settings, including hand hygiene and face masks. We reviewed evidence supporting the recommendations of these measures to prevent the spread of influenza in households.</div></div><div><h3>Methods</h3><div>We performed systematic reviews between 26 May and 30 August 2022 in Medline, PubMed, EMBASE, and CENTRAL to identify evidence for the effectiveness of selected measures recommended by representative national influenza pandemic plans. We prioritized evidence from randomized controlled trials conducted during influenza pandemics and seasonal influenza epidemics. Fixed-effects models were used to estimate the overall effects. Systematic reviews were registered in the OSF registry (<span><span>https://osf.io/8kyth</span><svg><path></path></svg></span>).</div></div><div><h3>Results</h3><div>We selected 9 NPIs for evidence review. We identified 9 randomized controlled trials related to hand hygiene and face masks in household settings. 2 studies reported that measures could delay the introduction of influenza virus infections into households. However, we did not identify evidence from randomized controlled trials that indicated a substantial effect of hand hygiene and face masks in preventing the spread of influenza within households.</div></div><div><h3>Conclusion</h3><div>Limited evidence indicated that within-household measures may likely be effective only when implemented before or as soon as possible after symptom onset in an infected case. Improving the evidence base for NPIs in households and elsewhere is a continuing priority.</div></div><div><h3>Funding</h3><div>World Health Organization and the Strategic Topic Grants Scheme.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"150 ","pages":"Article 107291"},"PeriodicalIF":4.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing central line-associated bloodstream infections: A position paper of the International Society for Infectious Diseases, 2024 update","authors":"Victor Daniel Rosenthal ,&nbsp;Ziad A. Memish ,&nbsp;FNU Shweta ,&nbsp;Gonzalo Bearman ,&nbsp;Larry I. Lutwick","doi":"10.1016/j.ijid.2024.107290","DOIUrl":"10.1016/j.ijid.2024.107290","url":null,"abstract":"<div><div>A panel of experts convened by the International Society for Infectious Diseases (ISID) has reviewed and consolidated current recommendations for preventing vascular catheter infections, particularly central line-associated bloodstream infections (CLABSIs). This review provides healthcare professionals with insights into key issues such as the rates of CLABSI in high-income countries and low- and middle-income countries, the attributable extra length of stay, cost and mortality, and risk factors. This position paper highlights evidence-based strategies for preventing infections, applicable to both high-income and low- and middle-income countries.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"150 ","pages":"Article 107290"},"PeriodicalIF":4.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare utilization among COVID-19 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study","authors":"Zaeema Naveed ,&nbsp;Julia Li ,&nbsp;James Wilton ,&nbsp;Monika Naus ,&nbsp;Héctor Alexander Velásquez García ,&nbsp;Nathaniel M. Hawkins ,&nbsp;Naveed Zafar Janjua ,&nbsp;on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators","doi":"10.1016/j.ijid.2024.107287","DOIUrl":"10.1016/j.ijid.2024.107287","url":null,"abstract":"<div><h3>Objectives</h3><div>We evaluated all-cause healthcare utilization among those with vaccine-associated myocarditis, compared to vaccinees without postvaccination myocarditis.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study in individuals aged 12 and older who received COVID-19 mRNA vaccination in British Columbia. Exposure was defined as an ED visit or hospitalization for myocarditis within 21 days postvaccination. The primary outcome was healthcare utilization. Ratios of rate ratios (RRRs) for exposure-associated healthcare utilization were calculated using a difference-in-differences (DiD) analysis.</div></div><div><h3>Results</h3><div>In the postindex period, the exposed and unexposed groups showed substantial utilization rate difference (RD = 15.30 [95% CI, 14.47-16.13). A 51% overall increase in healthcare utilization was observed over 18 months among exposed individuals (RRR, 1.51 [95%CI, 1.08-2.11]). In the initial six months, healthcare utilization surpassed the 18-month estimate, exhibiting a 125% increase (RRR, 2.25 [95%CI, 1.43-3.52]), while the last 12 months showed no statistically significant change (RRR, 1.03 [95%CI, 0.72-1.47]). An additional 9.1 (95%CI, 8.53-9.71) visits per person were attributed to vaccine-associated myocarditis over 18 months (total excess = 938.26 healthcare visits).</div></div><div><h3>Conclusion</h3><div>The initial surge in healthcare visits postexposure, mainly outpatient follow-ups, followed by a return to baseline rates, indicates a positive prognosis and supports the vaccine's safety profile.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"150 ","pages":"Article 107287"},"PeriodicalIF":4.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoantibodies directed against interferon alpha, nuclear antigens, cardiolipin, and beta 2 glycoprotein 1 are not induced by SARS-CoV-2 or associated with long COVID","authors":"Adam Epstein-Shuman ,&nbsp;Joanne H. Hunt ,&nbsp;Patrizio Caturegli ,&nbsp;Patrick Winguth ,&nbsp;Reinaldo E. Fernandez ,&nbsp;Gracie M. Rozek ,&nbsp;Xianming Zhu ,&nbsp;Nicholas A. DiRico ,&nbsp;Armaan Jamal ,&nbsp;Yu-Hsiang Hsieh ,&nbsp;Yukari C. Manabe ,&nbsp;Andrew D. Redd ,&nbsp;Steven J. Reynolds ,&nbsp;Annukka A.R. Antar ,&nbsp;Oliver Laeyendecker","doi":"10.1016/j.ijid.2024.107289","DOIUrl":"10.1016/j.ijid.2024.107289","url":null,"abstract":"<div><h3>Introduction</h3><div>Autoantibodies (AAbs) directed against interferon alpha (aIFNα), nuclear antigens (ANAs), anti-cardiolipin (aCL), and anti-beta 2 glycoprotein 1 (aβ2GP1), have been demonstrated to significantly correlate with the severity of acute Coronavirus Disease 2019 (COVID-19). However, whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection induces these AAbs and whether they are associated with long COVID remains unclear.</div></div><div><h3>Methods</h3><div>The potential induction of aIFNα, ANAs, aCL, and aβ2GP1 by SARS-CoV-2 was assessed by measuring these AAbs in 224 pre- and post-infection paired serum samples from the Johns Hopkins Hospital Emergency Department (JHHED). The relationship between these AAbs and long COVID was assessed using 60 serum samples from participants in the Outpatient SARS-CoV-2 Mild and Asymptomatic Infection Response and Transmission study.</div></div><div><h3>Results</h3><div>We found no evidence that these AAbs were induced in the JHHED cohort and no significant difference in their prevalence between patients with (<em>n</em> = 30) and without (<em>n</em> = 30) long COVID in the OutSMART cohort.</div></div><div><h3>Conclusion</h3><div>These findings do not support the hypotheses that SARS-CoV-2 induces these AAbs or that they are related to long COVID.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"150 ","pages":"Article 107289"},"PeriodicalIF":4.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in tuberculosis diagnostic delays between native and migrant populations in Italy: A multicenter study","authors":"Francesco Di Gennaro ,&nbsp;Sergio Cotugno ,&nbsp;Giacomo Guido ,&nbsp;Francesco Cavallin ,&nbsp;Mariantonietta Pisaturo ,&nbsp;Lorenzo Onorato ,&nbsp;Federica Zimmerhofer ,&nbsp;Luca Pipitò ,&nbsp;Giuseppina De Iaco ,&nbsp;Giuseppe Bruno ,&nbsp;Massimo Fasano ,&nbsp;Agostina Pontarelli ,&nbsp;Annarita Botta ,&nbsp;Tiziana Iacovazzi ,&nbsp;Rossana Lattanzio ,&nbsp;Virginia Di Bari ,&nbsp;Gianfranco Panico ,&nbsp;Raffaella Libertone ,&nbsp;Caterina Monari ,&nbsp;Alessia Musto ,&nbsp;Annalisa Saracino","doi":"10.1016/j.ijid.2024.107279","DOIUrl":"10.1016/j.ijid.2024.107279","url":null,"abstract":"<div><h3>Background</h3><div>Tuberculosis (TB) remains a Global Health challenge, with diagnostic delays contributing significantly to its spread. This study investigates the differences in diagnostic delays between native and migrant TB patients in Italy, examining patient-related diagnostic delay (PDD), health system-related diagnostic delay (HDD), and total diagnostic delay (TDD).</div></div><div><h3>Methods</h3><div>We conducted a retrospective, multicenter, cross-sectional study of TB cases in 10 Italian hospitals from 2018 to 2023. We compared PDD, HDD, and TDD between native and migrant populations. Socio-demographic data and clinical histories were analyzed to identify factors contributing to diagnostic delays.</div></div><div><h3>Results</h3><div>We included 669 TB patients (390 migrants and 279 natives). Migrants experienced significantly longer PDD (median 90 vs 10 days, <em>P</em> &lt; 0.0001) but shorter HDD (median 5 vs 40 days, <em>P</em> &lt; 0.0001) compared to natives, resulting in a longer TDD (median 96 vs 65 days, <em>P</em> &lt; 0.0001). Furthermore, migrants had higher Timika scores, longer sputum conversion times, and were more frequently lost to follow-up.</div></div><div><h3>Conclusion</h3><div>Migrants face longer PDD, emphasizing substantial barriers to healthcare access. Natives experience longer HDD, reflecting neglect of TB in low-endemic regions. Future research should focus on the impact of social determinants and training for healthcare providers on TB diagnosis and develop strategies to reduce diagnostic delays.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"150 ","pages":"Article 107279"},"PeriodicalIF":4.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dengue fever in immunocompromised patients: A systematic review and meta-analysis","authors":"Asma Sohail ,&nbsp;Shannon Zhong ,&nbsp;Phi-Yen Nguyen ,&nbsp;Sarah L. McGuinness ,&nbsp;Karin Leder","doi":"10.1016/j.ijid.2024.107272","DOIUrl":"10.1016/j.ijid.2024.107272","url":null,"abstract":"<div><h3>Objectives</h3><div>Given the complex role of immunity in dengue severity, we aimed to review the clinical course of dengue infection in immunocompromised patients.</div></div><div><h3>Methods</h3><div>We conducted a systematic review of studies reporting outcomes among immunocompromised patients with laboratory-confirmed dengue infection. Meta-analysis using the Mantel-Haenszel method (fixed effects) was performed for studies with control groups. We registered the study with PROSPERO (No. CRD42021258930).</div></div><div><h3>Results</h3><div>We included 115 studies. Among these, 30 studies compared immunocompromised (cases) and nonimmunocompromised (control) patients, focusing mainly on children (n = 22 studies) with malnutrition (n=18). Immunocompromised patients had a higher likelihood of dengue complications (OR 1.87; 95% CI: 1.04-3.35]) but a lower likelihood of severe dengue (OR 0.83; 95% CI: 0.69-1.00]. No significant difference in mortality was observed. In the 85 studies focused solely on immunocompromised patients, severe dengue and mortality rates were 9% and 4%, respectively, mostly among adult solid organ transplant recipients and those with inflammatory diseases. Immunosuppressive treatment alterations and temporary graft dysfunction were reported.</div></div><div><h3>Conclusion</h3><div>Immunocompromised patients have an increased risk of dengue-related complications. However, definitive conclusions about the comparative severity of dengue across different immunocompromised patient groups are limited by a lack of robust data, highlighting the need for well-designed future studies.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"149 ","pages":"Article 107272"},"PeriodicalIF":4.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}